Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Gene expression profile of immunoregulatory cytokines secreted from bone marrow and adipose derived human mesenchymal stem cells in early and late passages


Mesenchymal Stem Cells (MSCs) have therapeutic potential in a variety of diseases; however, the safety and efficacy of their use remain ambiguous. Clinical applications of MSCs are under intensive investigation due to their immunomodulatory features and lack of immune reactivity. Therefore, having a clear perspective on the exact mechanisms underlying the regulation of cytokine secretion in different microenvironments seems crucially important.

In the current study, samples from human bone marrow and adipose were collected, and peripheral blood mononuclear cells (PBMCs) were isolated and cultured in conventional medium. After MSC expansion, the cells from passage 3 (P3) and passage 9 (P9) were utilized to identify MSC cell surface markers and their differentiation capacity. The P3, P5, P7, and P9 cells were used for RNA extraction to qualify the expression of the main immunomodulatory cytokines IDO, VCAM-1, TGF-β, IL-6, IL-10, and PGE2 at mRNA levels. The results indicate that VCAM-1 expression in the subcultures was reduced in bone marrow-derived MSCs. After an increase in P5, P7, and P9, IL-6 expression was reduced. In adipose-derived MSCs, the mRNA levels of IL-10 in higher passages were decreased compared with P3; other studied cytokines had no significant changes in their expression levels in either bone marrow or adipose-derived MSCs. Based on these results, it can be concluded that a suitable source for MSCs in cell therapy with stable expression of main cytokines, even in higher subcultures, appears to be adipose-derived MSCs with the exception of IL-10 secretion.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. 1.

    Eyileten C, Majchrzak K, Pilch Z, Tonecka K, Mucha J, Taciak B, Rygiel TP (2016) Immune cells in cancer therapy and drug delivery. Mediat Inflamm. https://doi.org/10.1155/2016/5230219

  2. 2.

    Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, Wang Y (2018) Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol 14(8):493–507. https://doi.org/10.1038/s41581-018-0023-5

  3. 3.

    Trounson A, DeWitt ND (2016) Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol 17(3):194–200. https://doi.org/10.1038/nrm.2016.10

  4. 4.

    Yousaf Q, Tirmzi A, Ahsan S, Afroz A (2018) Multipotent potential of human adult mesenchymal stem cells. Biochem Mol Biol J 04(02):1–13. https://doi.org/10.21767/2471-8084.100065

  5. 5.

    Ullah I, Subbarao RB, Rho GJ (2015) Human mesenchymal stem cells—current trends and future prospective. Biosci Rep 35(2):1–18. https://doi.org/10.1042/BSR20150025

  6. 6.

    Gao F, Chiu SM, Motan DAL, Zhang Z, Chen L, Ji HL, Lian Q (2016) Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis 7(1):e2062. https://doi.org/10.1038/cddis.2015.327

  7. 7.

    Kordelas L, Rebmann V, Ludwig A, Radtke S, Ruesing J, Doeppner TR, Giebel B (2014) MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28(4):970–973. https://doi.org/10.1038/leu.2014.41

  8. 8.

    Leuning DG, Beijer NR, Du Fossé NA, Vermeulen S, Lievers E, Van Kooten C, De Boer J (2018) The cytokine secretion profile of mesenchymal stromal cells is determined by surface structure of the microenvironment. Sci Rep 8(1):1–9. https://doi.org/10.1038/s41598-018-25700-5

  9. 9.

    Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, Chang JW (2013) Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci 14(9):17986–18001

  10. 10.

    Ivanova-Todorova E, Bochev I, Dimitrov R, Belemezova K, Mourdjeva M, Kyurkchiev S, Kyurkchiev D (2012) Conditioned medium from adipose tissue-derived mesenchymal stem cells induces CD4+FOXP3+ cells and increases IL-10 secretion. J Biomed Biotechnol. https://doi.org/10.1155/2012/295167

  11. 11.

    Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W, Shao C (2010) Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 184(5):2321–2328. https://doi.org/10.4049/jimmunol.0902023.Inflammatory

  12. 12.

    Ankrum JA, Dastidar RG, Ong JF, Levy O, Karp JM (2014) Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids. Sci Rep 4:1–13. https://doi.org/10.1038/srep04645

  13. 13.

    Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim et Biophys Acta 1813(5):878–888. https://doi.org/10.1016/j.bbamcr.2011.01.034

  14. 14.

    Baghaei K, Hashemi SM, Tokhanbigli S, Rad AA, Assadzadeh-Aghdaei H, Sharifian A (2017) Isolation, differentiation, and characterization of mesenchymal stem cells from human bone marrow. Gastroenterol Hepatol Bed Bench 10(3):208–213. https://doi.org/10.22037/ghfbb.v0i0.1089

  15. 15.

    Salgado JA, Reis VR, Sousa N, Gimble MJ (2010) Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine. Curr Stem Cell Res Ther 5(2):103–110

  16. 16.

    Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, Kastrup J (2015) Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J 36(27):1744–1753. https://doi.org/10.1093/eurheartj/ehv136

  17. 17.

    Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, Jung HL (2009) Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol 259(2):150–156

  18. 18.

    Choi MR, Kim HY, Park JY, Lee TY, Baik CS, Chai YG, Kim KS (2010) Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci Lett 472(2):94–98

  19. 19.

    Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H (2013) Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med 2(6):455–463

  20. 20.

    Sepúlveda JC, Tomé M, Fernández ME, Delgado M, Campisi J, Bernad A, González MA (2014) Cell senescence abrogates the therapeutic potential of human mesenchymal stem cells in the lethal endotoxemia model. Stem Cells 32(7):1865–1877

  21. 21.

    Paladino FV, Sardinha LR, Piccinato CA, Goldberg AC (2017) Intrinsic variability present in wharton’s jelly mesenchymal stem cells and T cell responses may impact cell therapy. Stem Cells Int. https://doi.org/10.1155/2017/8492797

  22. 22.

    Kizilay Mancini O, Shum-Tim D, Stochaj U, Correa JA, Colmegna I (2015) Age, atherosclerosis and type 2 diabetes reduce human mesenchymal stromal cell-mediated T-cell suppression. Stem Cell Res Ther 6(1):6–10. https://doi.org/10.1186/s13287-015-0127-9

  23. 23.

    Kim JH, Jo CH, Kim HR, Hwang YI (2018) Comparison of immunological characteristics of mesenchymal stem cells from the periodontal ligament, umbilical cord, and adipose tissue. Stem Cells Int. https://doi.org/10.1155/2018/8429042

  24. 24.

    de Witte SF, Lambert EE, Merino A, Strini T, Douben HJ, O’Flynn L, Hoogduijn MJ (2017) Aging of bone marrow– and umbilical cord–derived mesenchymal stromal cells during expansion. Cytotherapy 19(7):798–807. https://doi.org/10.1016/j.jcyt.2017.03.071

  25. 25.

    Shibata KR, Aoyama T, Shima Y, Fukiage K, Otsuka S, Furu M, Toguchida J (2007) Expression of the p16INK4A gene is associated closely with senescence of human Mesenchymal stem cells and is potentially silenced by DNA methylation during in vitro expansion. Stem Cells 25(9):2371–2382. https://doi.org/10.1634/stemcells.2007-0225

Download references


The represented study was funded and supported by The Research Institute for Gastroenterology and Liver Diseases (RIGLD) with Grant No: 934, Shahid Beheshti University of Medical Sciences (Tehran, Iran).

Author information

Correspondence to Kaveh Baghaei.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Prior to conducting the research, current project’s protocols were reviewed and approved by the Shahid Beheshti University of Medical Sciences (SBMU) and the Research Institute for Gastroenterology and Liver Diseases (RIGLD) ethical committee. The approved code of ethics (Code of Ethics: IR.SBMU.RIGLD.RC.1396.123) was accordance with the ethical standards of these institutes.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Moghadam, M., Tokhanbigli, S., Baghaei, K. et al. Gene expression profile of immunoregulatory cytokines secreted from bone marrow and adipose derived human mesenchymal stem cells in early and late passages. Mol Biol Rep (2020). https://doi.org/10.1007/s11033-020-05264-2

Download citation


  • Bone marrow-derived MSCs
  • Adipose-derived MSCs
  • Inflammatory and anti-inflammatory cytokines
  • Passage number